尿CXCL10水平对PICU重症患儿死亡风险的预测价值

doi:10.12372/jcp.2024.23e0856

Abstract

Abstract:

Objective To investigate the predictive value of urinary CXC motif chemokine ligand 10 (uCXCL10) in the risk of death in critically ill children during their stay in the pediatric intensive care unit (PICU). Methods A total of 323 critically ill children admitted to PICU from September to December 2016 and from December 2017 to January 2018 were selected as the research objects. The patients were divided into survival group (295 cases) and death group (28 cases) according to the outcome during hospitalization in PICU, and the clinical characteristics of the children were compared between the groups. The uCXCL10 levels were serially measured during the first week after PICU admission using an enzyme-linked immunosorbent assay. Stepwise multivariate linear regression analysis were used to determine the correlation between uCXCL10 levels and clinical variables. Multivariate logistic regression analysis were performed to investigate the association of uCXCL10 with mortality after adjusting for confounders. The area under the ROC curve (AUC) was calculated to assess the predictive value of uCXCL10 in mortality of critically ill children. Results The initial and maximum values of uCXCL10 in the death group were significantly higher than those in the survival group (P<0.05). Both stepwise multivariate linear regression and multivariate logistic regression analysis showed that the initial and maximum values of uCXCL10 were significantly associated with mortality (P<0.05). The AUC values of initial and maximum uCXCL10 for predicting death in critically ill children were 0.780 (95%CI: 0.689-0.872, P<0.001) and 0.846 (95%CI: 0.769-0.923, P<0.001), respectively. Conclusion The uCXCL10 is an independent predictor of death in critically ill children.

Key words: mortality risk, urinary CXC motif chemokine ligand 10, predictive value, child

FENG Lian, HU Junlong, HUANG Hui, LI Xiaozhong, LI Yanhong. Predictive value of urinary CXCL10 for mortality risk of critically ill children in PICU[J].Journal of Clinical Pediatrics, 2024, 42(7): 631-636.

Figures/Tables 4

References 30

[1]	Gemke RJ, van Vught J. Scoring systems in pediatric intensive care: PRISM III versus PIM[J]. Intensive Care Med, 2002, 28(2): 204-207.
[2]	Joyce EL, Crana CM, Yabes J, et al. Validation of an electronic pediatric index of mortality 2 score in a mixed quaternary PICU[J]. Pediatr Crit Care Med, 2020, 21(8): e572-e575.
[3]	Matics TJ, Sanchez-Pinto LN. Adaptation and validation of a pediatric sequential organ failure assessment score and evaluation of the sepsis-3 definitions in critically ill children[J]. JAMA Pediatr, 2017, 171(10): e172352.
[4]	Tonial CT, Costa C, Andrades G, et al. Performance of prognostic markers in pediatric sepsis[J]. J Pediatr (Rio J), 2021, 97(3): 287-294.
[5]	Rey C, Fortenberry JD. Prognostic markers for pediatric septic shock: which ones, when, and how?[J]. Intensive Care Med, 2013, 39(10): 1851-1853. doi: 10.1007/s00134-013-3027-4 pmid: 23900580
[6]	Anil AB, Anil M, Yildiz M, et al. The importance of microalbuminuria in predicting patient outcome in a PICU[J]. Pediatr Crit Care Med, 2014, 15(5): e220-e225.
[7]	Nismath S, Rao SS, Baliga BS, et al. Comparative validity of microalbuminuria versus clinical mortality scores to predict pediatric intensive care unit outcomes[J]. Clin Exp Pediatr, 2020, 63(1): 20-24. doi: 10.3345/kjp.2018.07220 pmid: 31401824
[8]	Antonelli A, Ferrari SM, Giuggioli D, et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases[J]. Autoimmun Rev, 2014, 13(3): 272-280. doi: 10.1016/j.autrev.2013.10.010 pmid: 24189283
[9]	Elemam NM, Talaat IM, Maghazachi AA. CXCL10 chemokine: a critical player in RNA and DNA viral infections[J]. Viruses, 2022, 14(11): 2445.
[10]	Gao J, Wu L, Wang S, et al. Role of chemokine (C-X-C Motif) ligand 10 (CXCL10) in renal diseases[J]. Mediators Inflamm, 2020: 6194864.
[11]	Liu M, Guo S, Hibbert JM, et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications[J]. Cytokine Growth Factor Rev, 2011, 22(3): 121-130.
[12]	Jekarl DW, Kim JY, Ha JH, et al. Diagnosis and prognosis of sepsis based on use of cytokines, chemokines, and growth factors[J]. Dis Markers, 2019: 1089107.
[13]	Erez DL, Denburg MR, Afolayan S, et al. Acute kidney injury in children after hematopoietic cell transplantation is associated with elevated urine CXCL10 and CXCL9[J]. Biol Blood Marrow Transplant, 2020, 26(7): 1266-1272.
[14]	Huang H, Zhou H, Wang W, et al. Prediction of acute kidney injury, sepsis and mortality in children with urinary CXCL10[J]. Pediatr Res, 2022, 92(2): 541-548.
[15]	Hoste E, Kellum JA, Selby NM, et al. Global epidemiology and outcomes of acute kidney injury[J]. Nat Rev Nephrol, 2018, 14(10): 607-625. doi: 10.1038/s41581-018-0052-0 pmid: 30135570
[16]	Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study[J]. Lancet, 2020, 395(10219): 200-211. doi: S0140-6736(19)32989-7 pmid: 31954465
[17]	Amecican Academy of Pediatrics, Commitee on Hospitial Care and Society of Critial Care, Society of Critial Care Medicine, et al. Guidelines for developing admission and discharge policies for the pediatric[J]. Pediatrics, 1999(103): 840-842.
[18]	Weiss SL, Peters MJ, Alhazzani W, et al. Executive summary: surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children[J]. Pediatr Crit Care Med, 2020, 21(2): 186-195.
[19]	Khwaja A. KDIGO clinical practice guidelines for acute kidney injury[J]. Nephron Clin Pract, 2012, 120(4): c179-c184.
[20]	Fang F, Hu X, Dai X, et al. Subclinical acute kidney injury is associated with adverse outcomes in critically ill neonates and children[J]. Crit Care, 2018, 22(1): 256.
[21]	Herzig DS, Luan L, Bohannon JK, et al. The role of CXCL10 in the pathogenesis of experimental septic shock[J]. Crit Care, 2014, 18(3): R113.
[22]	Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases[J]. Autoimmun Rev, 2009, 8(5): 379-383. doi: 10.1016/j.autrev.2008.12.002 pmid: 19105984
[23]	Chan T, Gu F. Early diagnosis of sepsis using serum biomarkers[J]. Expert Rev Mol Diagn, 2011, 11(5):487-496. doi: 10.1586/ERM.11.26 pmid: 21707457
[24]	Vaidya VS, Waikar SS, Ferguson MA, et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans[J]. Clin Transl Sci, 2008, 1(3): 200-208. doi: 10.1111/j.1752-8062.2008.00053.x pmid: 19212447
[25]	程创, 石中全. miR-16-5p靶向抑制CXCL10表达减轻脂多糖诱导的HK-2人肾小管上皮细胞损伤[J]. 细胞与分子免疫学杂志, 2022, 38(3): 218-223.
[26]	Kirita Y, Wu H, Uchimura K, et al. Cell profiling of mouse acute kidney injury reveals conserved cellular responses to injury[J]. Proc Natl Acad Sci U S A, 2020, 117(27): 15874-15883.
[27]	Lehmann JM, Claus K, Jansen C, et al. Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality[J]. Liver Int, 2018, 38(5): 875-884. doi: 10.1111/liv.13610 pmid: 29105936
[28]	Landreneau MJ, Mullen MT, Messe SR, et al. CCL2 and CXCL10 are associated with poor outcome after intracerebral hemorrhage[J]. Ann Clin Transl Neurol, 2018, 5(8): 962-970.
[29]	Tinel C, Vermorel A, Picciotto D, et al. Deciphering the prognostic and predictive value of urinary CXCL10 in kidney recipients with BK virus reactivation[J]. Front Immunol, 2020, 11: 604353.
[30]	Tinel C, Devresse A, Vermorel A, et al. Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection[J]. Am J Transplant, 2020, 20(12): 3462-3476.

项目	存活组（n=295）	死亡组（n=28）	统计量	P
年龄[M(P₂₅~P₇₅)]/月	17.0(3.1~56.0)	20.5(8.4~71.8)	Z=1.23	0.194
体重[M(P₂₅~P₇₅)]/kg	11.0(6.6~18.0)	12.5(7.9~23.8)	Z=1.03	0.303
性别(男)[n(%)]	197(66.8)	21(75.0)	χ²=0.78	0.375
PRISM Ⅲ[M(P₂₅~P₇₅)]/分	3(0~8)	14(7~28.8)	Z=5.69	<0.001
AKI[n(%)]	34(11.5)	15(53.6)	χ²=31.94	<0.001
AKI 1期[n(%)]	15(5.1)	6(21.5)	χ²=11.88	0.003
AKI 2期[n(%)]	13(4.4)	0(0.0)
AKI 3期[n(%)]	6(2.0)	9(32.1)
脓毒症[n(%)]	107(36.3)	14(50.0)	χ²=2.06	0.151
MODS[n(%)]	16(5.4)	18(64.3)	χ²=87.93	<0.001
休克/DIC[n(%)]	21(7.1)	9(32.1)	χ²=16.15	<0.001
MV[n(%)]	58(19.7)	25(89.3)	χ²=64.92	<0.001
RRT[n(%)]	12(4.1)	4(14.3)	χ²=3.71	0.054
正性肌力药[n(%)]	22(7.5)	9(32.1)	χ²=15.23	<0.001
利尿剂[n(%)]	25(8.5)	12(42.9)	χ²=26.51	<0.001
激素[n(%)]	161(54.6)	21(75.0)	χ²=4.34	0.037
抗生素[n(%)]	231(78.3)	24(85.7)	χ²=0.85	0.358
PICU时长[M(P₂₅~P₇₅)]/ h	87.5(46.0~148.0)	167.8(63.0~420.0)	Z=2.76	0.006
uCXCL10初始值/uCr[M(P₂₅~P₇₅)]/ng·mg^-1	0.09(0.04~0.25)	0.80(0.14~2.98)	Z=4.90	<0.001
uCXCL10最大值/uCr[M(P₂₅~P₇₅)]/ng·mg^-1	0.11(0.05~0.35)	2.04(0.45~3.75)	Z=6.50	<0.001

因素	uCXCL10初始值			uCXCL10最大值
因素	β	S.E.	P	β	S.E.	P
体重	NA	NA	NA	-0.009	0.003	0.005
AKI分期	NA	NA	NA	0.124	0.051	0.015
脓毒症	0.189	0.076	0.013	0.192	0.072	0.008
休克/DIC	0.384	0.130	0.003	0.406	0.127	0.001
临床结局	0.682	0.132	<0.001	0.733	0.132	<0.001

因素	OR	95%CI	P	AOR	95%CI	P
尿CXCL10初始值	4.295	2.458~7.503	<0.001	4.079^1）	1.676~9.929	0.002
尿CXCL10最大值	6.118	3.343~11.453	<0.001	5.421^1）	2.114~13.904	<0.001

Predictive value of urinary CXCL10 for mortality risk of critically ill children in PICU

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 30

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LIN Jinfeng, CHEN Yi, DENG Yan, FENG Ai, HUANG Juan, CHEN Lizhu, XIE Jingqi, NIE Xiaojing. A comparative study on the detection of anti-Nephrin antibodies in children's nephrotic syndrome by chemiluminescence method and cell-based assay [J]. Journal of Clinical Pediatrics, 2026, 44(8): 682-689.
[2]	ZHENG Fangyuan, WANG Miao, DING Mingming, LU Aidong, JIA Yueping, ZENG Huimin, ZHANG Leping. Next-generation sequencing identified gene variants and their prognostic impact in pediatric Philadelphia chromosome positive acute lymphoblastic leukemia [J]. Journal of Clinical Pediatrics, 2026, 44(8): 690-697.
[3]	ZHANG Xiao, FANG Hongjun, KUANG Xiaojun, WANG Lijuan, WU Zhao, JIANG Sha, LI Pei, WU Liwen. Analysis of the clinical and electrophysiological characteristics of atonic seizures in children [J]. Journal of Clinical Pediatrics, 2026, 44(8): 698-704.
[4]	WANG Mengqian, YANG Hui. Case series analysis of 13 intestinal Behcet’s syndrome in children [J]. Journal of Clinical Pediatrics, 2026, 44(8): 705-711.
[5]	WU Xirong, GAO Qi, GUO Siyuan, YIN Qingqin, QIN Qiang, YIN Ju, JIAO Anxia, CHEN Chenghao, WU Di, WANG Bei, DUAN Xiaomin, PENG Yun, XU Baoping, GAO Liwei. Clinical characteristics and prognosis of pulmonary mucormycosis in children with diabetes mellitus [J]. Journal of Clinical Pediatrics, 2026, 44(8): 712-720.
[6]	HAN Yanan, GE Lanlan, CUI Jieyuan. A case report of branchio-oto-renal syndrome caused by EYA1 gene variant with a 6-year follow-up [J]. Journal of Clinical Pediatrics, 2026, 44(8): 721-726.
[7]	SHI Jiayi, GAO Chunlin, JIA Lili, LU Yunyun, SUN Tao, ZHU Xiaodong, XIA Zhengkun, ZHANG Pei. Phenotypic characteristics and prognostic analysis of a pedigree with childhood isolated nephrotic syndrome caused by compound heterozygous mutations in the COQ2 gene [J]. Journal of Clinical Pediatrics, 2026, 44(8): 727-732.
[8]	Rachel Rosen, Osvaldo Borrelli, Christophe Faure, Katja Karrento, Usha Krishnan, Samuel Nurko, Nathalie Rommel, Alan Silverman, Michiel van Wijk, Marc Benninga (Author), Chinese Medical Association Parenteral and Enteral Nutrition Branch Pediatrics Group, The Subspecialty Group of Gastroenterology, The Society of Pediatric, Chinese Medical Association, Gastroenterology Group, Pediatrician Branch, Chinese Medical Doctor Association (Translator). Core interpretation and explanation of Rome Ⅴ diagnostic criteria: upper gastrointestinal disorders of gut-brain interaction in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(7): 595-608.
[9]	Carlo Di Lorenzo, Miguel Saps, Bruno P. Chumpitazi, Shaman Rajindrajith, Annamaria Staiano, Nikhil Thapar, Miranda van Tilburg, Carlos Velasco-Benítez, Arine Vlieger (Author), Chinese Medical Association Parenteral and Enteral Nutrition Branch Pediatrics Group, The Subspecialty Group of Gastroenterology, The Society of Pediatric, Chinese Medical Association, Gastroenterology Group, Pediatrician Branch, Chinese Medical Doctor Association (Translator). Core interpretation and explanation of Rome Ⅴ diagnostic criteria: lower and biliary disorders of gut-brain interaction in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(7): 609-621.
[10]	LI Xufeng, TANG Haoxun, LI Xingjun, ZHANG Lize, GAO Chenqing, ZHAO Shunying, LIU Jianhua. Clinical characteristics, chest CT imaging phenotypes, and their correlation with prognosis in 76 children with Chlamydia pneumoniae pneumonia [J]. Journal of Clinical Pediatrics, 2026, 44(7): 622-627.
[11]	WANG Zhen, SHAO Jingbo, ZHANG Na, XIA Min, ZHU Jiashi, DU Chengkan, LI Hong. Factors influencing long-term recurrence in pediatric acute lymphoblastic leukemia patients with low-risk disease at initial diagnosis: a five-year follow-up analysis of 254 cases from a single center [J]. Journal of Clinical Pediatrics, 2026, 44(7): 628-635.
[12]	GUO Xuemei, XUE Yao, WANG Yongren, RONG Liucheng, FANG Yongjun, LIN Rufeng. Clinical features and prognosis of childhood acute myeloid leukemia with CBFA2T3::GLIS2 fusion [J]. Journal of Clinical Pediatrics, 2026, 44(7): 636-643.
[13]	YANG Lijun, FU Dongxia, CUI Yan, YANG Junmei, ZHANG Liming. Clinical manifestation and genetic analysis of CHARGE syndrome caused by CHD7 gene variation [J]. Journal of Clinical Pediatrics, 2026, 44(7): 644-650.
[14]	HU Yan, YANG Fan, LIANG Aimin, MAO Meng. Identification and management of faltering growth in children: insights from the 13th International Conference on Nutrition and Growth [J]. Journal of Clinical Pediatrics, 2026, 44(6): 485-488.
[15]	LIU Ziyao, WANG Congying, WANG Hongmao, ZHANG Mingming, XU Yingjie, LAI Jianming, NIU Wenquan, LI Xiaohui. Early differentiation of Kawasaki disease with joint symptoms and systemic juvenile idiopathic arthritis with Kawasaki disease-like symptoms: a single-center retrospective study [J]. Journal of Clinical Pediatrics, 2026, 44(6): 489-498.